SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities
In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...
Sage Therapeutics price target raised to $9 from $6 at Mizuho
Mizuho raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $6 and keeps a Neutral rating on the shares. The firm reassessed ...
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...
EconoTimes3d
Sage Therapeutics Rejects Biogen’s $469M Offer, Citing Undervaluation
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...
Yahoo Finance3d
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
January 27, 2025--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic ...
Sage Therapeutics Initiates Strategic Review Process and Rejects Proposal from Biogen
Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...
The Business Journals4d
Sage rejects Biogen’s buyout offer, but says it's open to deals
The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...
Investing4d
Sage Therapeutics shares rise amid strategic review
Investing.com -- Sage Therapeutics, Inc. (NASDAQ:SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the initiation of a strategic review process and the ...
Nasdaq3d
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...
Yahoo Finance4d
Sage rejects Biogen's $469 million takeover offer
(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of ...
Mizuho raises Sage Therapeutics target to $9 on Biogen bid
Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...